MGI/Helsinn’s Aloxi Adds Multi-Day Dosing To Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Antiemetic injection is cleared to remove seven-day interval limitation from label for nausea and vomiting associated with chemotherapy.
You may also be interested in...
Eisai Wins Post-Operative Indication For Antiemetic Aloxi
Gained through the acquisition of MGI Pharma, drug adds indication for post-operative nausea and vomiting.
Eisai Wins Post-Operative Indication For Antiemetic Aloxi
Gained through the acquisition of MGI Pharma, drug adds indication for post-operative nausea and vomiting.
MGI Pharma Boosts Hematology Pipeline With AkaRx Agreement
Phase II thrombocytopenia candidate AKR-501 has revenue potential in excess of $1 billion in the U.S., MGI says.